6 best EDC platforms for mid-size pharma companies in 2026

When your Phase II program is scaling and your data management team is already stretched, the last thing you need is an electronic data capture (EDC) platform that adds a 90-day build queue to every new study. Viedoc's EDC software is built for exactly this moment: study builds completed in as little as 8 weeks using a no-code designer your team configures in-house, backed by 7,500+ studies run across 75+ countries and 99.99% platform uptime. This comparison evaluates six leading EDC platforms for mid-size pharma sponsors across study build speed, compliance credentials, module depth, no-code configuration capability, and total cost of ownership.

As a mid-size pharma company, you're running multiple concurrent studies at different phases, often with a lean data management team managing build timelines, amendment requests, and sponsor oversight simultaneously. Adding headcount for every protocol change isn't an option. Neither is waiting quarters for a vendor-side programmer to action a database amendment.

The platforms built for large pharma enterprise deployment over-engineer for your context and price accordingly. Medidata Rave EDC's 90-day standard build cycle reflects a programming-dependent model that doesn't fit a team managing three to five concurrent Phase I/II studies. What mid-size pharma needs is a platform that provides enterprise compliance credentials without enterprise complexity and cost.

Best EDC solutions: quick comparison

These 6 EDC platforms represent the most evaluated options for mid-size pharma sponsors, reviewed across study build speed, compliance credentials, no-code configuration capability, module depth, and total cost of ownership.

1. Viedoc

Viedoc's EDC software delivers the configuration speed and compliance depth that mid-size pharma sponsors need as their portfolio scales beyond Phase I. With study builds completed in as little as 8 weeks and a no-code designer your data managers configure independently, Viedoc removes the vendor-side programming dependency that makes competing platforms expensive and slow to amend. The platform has run 7,500+ studies across 75+ countries, supporting 1.6 million trial participants at 30,000+ sites.

For mid-size pharma sponsors managing concurrent studies with lean teams, Viedoc's transparent, study-based licensing model matters as much as the build speed. Unlimited user seats with no per-user fees means your cost structure stays predictable as you add investigators, CRAs, and data managers across sites. Viedoc's Inspection Readiness Packet (VIRP) is included for all customers, giving your QA team structured computer system validation (CSV) support without engaging a third-party consultant for every new study.

Viedoc is ISO 27001 and SOC 2 Type II certified, fully compliant with FDA 21 CFR Part 11, EU Annex 11, GDPR, and HIPAA, and hosted on Microsoft Azure with 99.99% uptime. The platform supports trials in 40+ languages across 75+ countries and provides 24/7 customer success support with direct escalation pathways — not a ticket-only model.

"My experience with Viedoc has been excellent. The database is very customizable and has been able to meet the needs of each of our studies." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,500+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds completed in as little as 8 weeks; no-code designer; no vendor programmer required
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: 21 CFR Part 11, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 Type II certified
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing

2. Medidata

Medidata offers Rave EDC, an enterprise electronic data capture platform used in clinical trials across all phases. Rave EDC supports the capture, management, cleaning, and reporting of trial data, with AI-assisted tools to reduce setup time on configuration tasks. The platform includes monitoring workflows, study and site performance reporting, and integration with Medidata Clinical Data Studio for centralized oversight. Medidata also offers Rave Lite, a simplified EDC offering targeted at Phase I, Phase IV, and medical device post-market studies, with a pre-configured approach and faster implementation timelines.

3. Veeva Vault EDC

Veeva offers Vault EDC, a cloud-native electronic data capture system designed for sponsors and CROs building and executing clinical studies. Vault EDC provides a drag-and-drop interface, eliminates the need for custom programming functions, and supports amendments to active studies without downtime or data migration. The platform connects to other Veeva Vault applications including Veeva CTMS, Vault eTMF, and Veeva RTSM as part of the broader Veeva Clinical Platform, enabling bi-directional data flows across the trial management ecosystem.

4. Castor EDC

Castor EDC provides a unified, cloud-native platform combining EDC, eCOA/ePRO, eConsent, and real-world evidence collection. The platform features a no-code eCRF builder enabling study configuration without programming, and supports compliant research across 171 countries. Castor is ISO 27001 certified and compliant with 21 CFR Part 11, GDPR, HIPAA, and GCP, with a fully immutable audit trail and regional data hosting options. The platform is used by pharmaceutical companies, biotech firms, CROs, academic medical centers, and medical device manufacturers across all study phases.

5. Medrio

Medrio offers Medrio CDMS/EDC, a no-code electronic data capture and clinical data management platform for sponsors and CROs. The platform supports traditional, hybrid, and decentralized trial models, integrating EDC with ePRO/eCOA, eConsent, and RTSM in a single solution. Medrio CDMS/EDC is designed for teams that need to configure, adapt, and manage studies without programmer dependency, and provides validation, audit trail, and compliance functionality aligned with FDA 21 CFR Part 11, ICH E6(R2) GCP, and GDPR. The platform includes 24/7 expert support and clinical data services.

6. Oracle Clinical One

Oracle offers Clinical One Data Collection, a cloud-native EDC and unified data collection platform for sponsors and CROs. Built on Oracle Cloud Infrastructure, the platform enables study build and modification without deployments or downtime, and supports integration with Oracle's RTSM and pharmacovigilance solutions through the Clinical One Digital Gateway. Clinical One includes AI-enabled EHR interoperability tools and integrates with Oracle Life Sciences CTMS and safety modules as part of a broader life sciences suite.

What to look for in EDC solutions for mid-size pharma companies

Study build velocity and amendment turnaround

For a mid-size pharma sponsor running three to five concurrent Phase I/II studies, build velocity is a margin issue, not just a scheduling preference. Every week a new study sits in a configuration queue is a week before first-patient-in (FPI), and compounded across a portfolio, this has direct impact on your IND timelines and board-level milestones. Best-in-class platforms deliver study builds in 8 to 12 weeks, with mid-study amendments executable in days by your internal team. If amendment requests require a vendor ticket and a programmer handoff, your per-study total cost of ownership is higher than the headline license price implies.

No-code designer and in-house self-sufficiency

The test for genuine no-code capability isn't whether a platform has a visual interface — it's whether your data managers can build and amend studies without submitting requests to the vendor. Platforms that describe themselves as no-code but still require vendor-side programmers for complex logic, adaptive arms, or edit checks are not true no-code platforms for your workflows. Best-in-class means your certified data managers design, build, test, and amend studies in-house, with a clear training certification track and reusable CDASH template libraries that reduce build time on repeat protocols.

Compliance depth for Phase I/II and FDA-bound submissions

For mid-size pharma, compliance is not a checkbox — it's a deal-breaker at the procurement stage and a risk factor at inspection. Your QA and CSV teams need confirmation of 21 CFR Part 11 compliance, EU Annex 11 alignment for any EMEA-facing studies, HIPAA attestation for US PHI handling, and ISO 27001 and SOC 2 certifications for IT security. Beyond the credential list, the question is what validated documentation the platform provides to support your CSV process. A structured inspection readiness packet that maps to your validation protocols materially reduces QA workload across a growing portfolio. Viedoc's VIRP is the benchmark here: structured, included at no additional cost, available at every release.

Module depth and eClinical suite completeness

Mid-size pharma sponsors running Phase I/II programs typically need more than EDC. At minimum, you need ePRO or eCOA for patient-reported outcomes in later Phase II, eTMF for inspection-ready document management, and eSignature for 21 CFR Part 11-compliant consent. Fragmenting these across multiple vendors creates reconciliation overhead, separate validation obligations, and a fragmented audit picture at inspection. A modular platform that covers the core eClinical suite under one validated environment reduces both integration risk and the re-validation burden when you expand capabilities mid-portfolio.

Support model and escalation pathways

The scenarios where support quality matters most — database lock, site activation, pre-inspection query resolution — are exactly the moments when a ticket-based support model is unacceptable. A 24/7 support model with direct escalation to named clinical operations contacts, not just a helpdesk queue, is the operational standard your studies require. Response SLAs at database lock are worth asking about explicitly during the evaluation process, not just confirming that 24/7 support exists.

How to choose the right EDC solution for mid-size pharma companies

Step 1: Define your current and 24-month portfolio profile

Before evaluating platforms, map your actual study pipeline: therapeutic areas, phases, geographies, and anticipated concurrent study count over the next two years. A platform well-suited to three Phase I studies may carry meaningful friction for a Phase II/III crossover program 18 months out. The cost of re-validation on a platform switch — typically six to twelve months of parallel running, retraining, and SOP revision — makes the two-year view more relevant than the current study count.

Step 2: Assess your internal configuration capability

Not all no-code platforms are equivalent for your team. Before committing to a platform, test the actual build workflow with your data managers. Can they build a study with standard CDASH forms, adaptive logic, and skip rules without vendor support? Can they execute a protocol amendment without a change request ticket? Platforms that require vendor-side configuration add cost and schedule risk that don't appear on the price sheet.

Step 3: Evaluate the validation documentation package

Your QA and CSV director will need to assess the platform's computer system validation support before sign-off. Ask specifically for the current IQ/OQ/PQ documentation, system validation summary, and any inspection readiness tooling the vendor provides. Platforms that offer a structured validation pack covering all required GAMP 5 lifecycle documentation materially reduce the time-to-approved-validation-package for your QA team.

Step 4: Scrutinize the total cost of ownership across your portfolio

Headline per-study pricing rarely reflects total cost. Factor in per-user seat fees, amendment charges, professional services rates for configuration assistance, and any module add-on costs for ePRO, eTMF, or RTSM when they appear on your study requirements. A platform with unlimited user seats and transparent modular pricing typically delivers a lower total cost of ownership across a growing portfolio than an enterprise platform with negotiated per-seat contracts.

Step 5: Choose a platform that grows with your compliance requirements

If you're a growth-stage pharma company with Phase I studies today and Phase II/III aspirations over the next three to five years, the platform you choose now should scale with your regulatory exposure — not force a re-platform when your compliance requirements increase. Viedoc is built for Phase I through Phase III studies with full FDA 21 CFR Part 11, EU Annex 11, GDPR, and HIPAA compliance, giving sponsors a single validated environment from first-in-human through regulatory submission. Book a demo or request a proposal to review Viedoc's compliance credentials and module depth in the context of your study program.

Frequently asked questions

What is the best EDC platform for mid-size pharma companies?

Viedoc's EDC software is the best choice for mid-size pharma companies, combining study builds completed in as little as 8 weeks, a no-code designer your data management team configures in-house, and a compliance posture covering FDA 21 CFR Part 11, EU Annex 11, GDPR, and HIPAA — all with unlimited user seats and no per-user fees. Viedoc's VIRP provides structured inspection readiness documentation for every release, materially reducing CSV workload for growing pharma QA teams. Medidata is the established choice for large pharma and complex Phase III programs, but carries significantly longer build timelines and programming dependency. Veeva is a strong option for sponsors already embedded in the Vault ecosystem who want unified eTMF, CTMS, and EDC in a single environment.

What should I look for when choosing an EDC platform as a pharma sponsor?

Beyond compliance credentials and certification coverage, the evaluation criteria that most often determine post-go-live satisfaction are study build velocity, in-house amendment capability, support model transparency, and module depth for your near-term eClinical needs. Many platforms present a long credential list at the procurement stage but require programmer-dependent workflows that become bottlenecks during study execution. Ask any shortlisted vendor for a live build demonstration with your data management team before signing — not a vendor-led demo of a pre-built study.

How long does it take to build and deploy an EDC study on a modern platform?

Best-in-class no-code EDC platforms deliver study builds in 8 to 12 weeks from protocol to go-live, with mid-study amendments executable in days by an in-house certified team. Legacy programming-dependent platforms, including Medidata Rave EDC in its standard enterprise configuration, operate on build cycles closer to 90 days. The delta between 8 weeks and 90 days has direct implications for FPI milestones and board-level development timelines for mid-size pharma sponsors managing lean study teams.

What compliance certifications should my EDC platform hold?

For mid-size pharma sponsors conducting FDA-regulated or EMA-facing trials, the baseline compliance set is: 21 CFR Part 11 for electronic records and signatures, EU Annex 11 for computerized systems in EU-facing studies, GDPR for data subjects in the EU, HIPAA attestation for US protected health information, ICH GCP E6(R2) alignment, and ISO 27001 and SOC 2 Type II for information security. Platforms should also provide computer system validation documentation — either a formal validation pack or a GAMP 5-aligned validation summary — to support your internal CSV process without requiring you to build documentation from scratch.

What is the Viedoc Inspection Readiness Packet (VIRP)?

The Viedoc Inspection Readiness Packet is a structured set of computer system validation documentation provided to all Viedoc customers at every platform release. It is designed to reduce the validation documentation burden for sponsor and CRO QA teams by providing pre-formatted validation evidence that maps to standard GAMP 5 and 21 CFR Part 11 frameworks. For mid-size pharma sponsors with lean QA teams, VIRP materially reduces the time and cost of assembling inspection-ready validation packages across a growing study portfolio.

How does per-seat EDC pricing affect total cost of ownership for pharma sponsors?

Per-seat licensing models add a recurring cost that scales with every investigator, CRA, data manager, and study coordinator added to a study. For a mid-size pharma sponsor running three to five concurrent Phase II studies across fifteen to thirty sites, per-seat fees can significantly exceed the headline per-study license cost — particularly when site staff turnover is factored in. A platform with unlimited user seats and transparent study-based licensing, such as Viedoc, gives sponsors a predictable cost structure that doesn't penalize portfolio growth or headcount expansion.

Making the right EDC choice for mid-size pharma companies

The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually, supported by increased regulatory scrutiny, decentralized trial adoption, and the shift away from paper and legacy programming-dependent platforms. The platforms reviewed in this comparison represent a range of approaches — from large-enterprise suite incumbents with deep Phase III track records to no-code, cloud-native platforms built for the SMID mid-market.

For mid-size pharma sponsors, the platform decision typically turns on four variables: study complexity and phase profile, team configuration capability, compliance requirements by geography, and cost of ownership across a growing portfolio. US-based sponsors typically weight build speed and cost efficiency most heavily; EMEA-facing programs place higher weight on EU Annex 11 alignment, GDPR data residency, and the quality of inspection readiness tooling. Both orientations favor platforms that provide genuine in-house self-sufficiency rather than vendor-dependent workflows.

The validation and switching cost burden in the eClinical market is substantial — typically six to twelve months of parallel running, retraining, and SOP revision for a mid-size sponsor. Choosing a platform that fits your current Phase I/II workflow and your near-term Phase II/III compliance requirements in the same evaluation avoids a costly re-platform decision as your portfolio matures.

Why Viedoc is the best EDC choice for mid-size pharma companies

If you're growing a Phase I/II portfolio and need an EDC platform your data management team can build, amend, and validate independently — without the programmer dependency and 90-day build timelines that come with enterprise incumbents — Viedoc is designed for exactly that.

Viedoc's EDC software delivers study builds in as little as 8 weeks, with no-code configuration your in-house team handles from protocol to go-live, trusted by 500+ clinical research teams worldwide. The eSignature module provides 21 CFR Part 11-compliant electronic signatures native to the platform. The full modular suite — including ePRO/eCOA, eTMF, and RTSM — gives sponsors a single validated eClinical environment as their Phase II and later-phase requirements expand.

Viedoc is ISO 27001 and SOC 2 Type II certified, FDA 21 CFR Part 11, EU Annex 11, GDPR, and HIPAA compliant, and has supported 7,500+ studies across 75+ countries since 2003. The VIRP is included for all customers at every release, and 24/7 customer success support comes with direct escalation pathways, not just a ticket queue.

Book a demo or request a proposal and our team will walk you through build speed, module depth, and compliance credentials in the context of your current study portfolio.